Quadrant Capital Management LLC boosted its holdings in Thermo Fisher Scientific Inc (NYSE:TMO) by 3.3% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 14,318 shares of the medical research company’s stock after buying an additional 455 shares during the quarter. Thermo Fisher Scientific accounts for about 2.0% of Quadrant Capital Management LLC’s investment portfolio, making the stock its 22nd largest position. Quadrant Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $2,709,000 as of its most recent filing with the SEC.
A number of other institutional investors have also bought and sold shares of the business. Proficio Capital Partners LLC grew its position in Thermo Fisher Scientific by 71.5% during the 1st quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock worth $105,000 after purchasing an additional 253 shares in the last quarter. Chicago Partners Investment Group LLC purchased a new position in Thermo Fisher Scientific during the 2nd quarter worth approximately $108,000. Shine Investment Advisory Services Inc. acquired a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at $113,000. Ropes Wealth Advisors LLC boosted its stake in shares of Thermo Fisher Scientific by 15.8% during the 2nd quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock valued at $124,000 after buying an additional 97 shares during the period. Finally, Atlantic Trust LLC acquired a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at $138,000. Hedge funds and other institutional investors own 86.16% of the company’s stock.
In other news, CEO Marc N. Casper sold 50,000 shares of the business’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $188.39, for a total transaction of $9,419,500.00. Following the transaction, the chief executive officer now owns 252,577 shares in the company, valued at approximately $47,582,981.03. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.49% of the company’s stock.
Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.24 by $0.07. The firm had revenue of $5.12 billion during the quarter, compared to analyst estimates of $5.03 billion. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The business’s revenue was up 13.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.03 EPS. analysts forecast that Thermo Fisher Scientific Inc will post 9.36 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, January 15th. Stockholders of record on Friday, December 15th will be issued a dividend of $0.15 per share. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $0.60 annualized dividend and a dividend yield of 0.33%. Thermo Fisher Scientific’s payout ratio is 10.19%.
A number of brokerages have issued reports on TMO. Jefferies Group reissued a “hold” rating and set a $195.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, September 28th. Leerink Swann reissued an “outperform” rating and set a $200.00 target price (down previously from $216.00) on shares of Thermo Fisher Scientific in a research note on Monday. Goldman Sachs Group began coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, September 26th. They set a “buy” rating and a $225.00 target price for the company. Barclays reissued an “overweight” rating and set a $215.00 target price (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Monday, September 25th. Finally, Argus reissued a “buy” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, August 22nd. They noted that the move was a valuation call. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $205.21.
ILLEGAL ACTIVITY NOTICE: This report was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.chaffeybreeze.com/2017/12/06/quadrant-capital-management-llc-acquires-455-shares-of-thermo-fisher-scientific-inc-tmo.html.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.